Abstract:

BACKGROUND: For people living with HIV, major guidelines in high-income countries recommend testing for transmitted drug resistance (TDR) to guide the choice of first-line antiretroviral therapy (ART). However, individuals who fail a first-line regimen can now be switched to one of several effective regimens. Therefore, the virological and clinical benefit of TDR testing needs to be evaluated. METHODS: We included individuals from the HIV-CAUSAL Collaboration who enrolled <6 months of HIV diagnosis between 2006 and 2015, were ART-naive, and had measured CD4 count and HIV-RNA. Follow-up started at the date when all inclusion criteria were first met (baseline). We compared 2 strategies: (1) TDR testing within 3 months of baseline versus (2) no TDR testing. We used inverse probability weighting to estimate the 5-year proportion and hazard ratios (HRs) of virological suppression (confirmed HIV-RNA <50 copies/mL), and of AIDS or death under both strategies. RESULTS: Of 25,672 eligible individuals (82% males, 52% diagnosed in 2010 or later), 17,189 (67%) were tested for TDR within 3 months of baseline. Of these, 6% had intermediate- or high-level TDR to any antiretroviral drug. The estimated 5-year proportion virologically suppressed was 77% under TDR testing and 74% under no TDR testing; HR 1.06 (95% confidence interval: 1.03 to 1.19). The estimated 5-year risk of AIDS or death was 6% under both strategies; HR 1.03 (95% confidence interval: 0.95 to 1.12). CONCLUSIONS: TDR prevalence was low. Although TDR testing improved virological response, we found no evidence that it reduced the incidence of AIDS or death in first 5 years after diagnosis.

Notes:

1944-7884Lodi, SaraGünthard, Huldrych FGill, JohnPhillips, Andrew NDunn, DavidVu, QuangSiemieniuk, ReedGarcia, FedericoLogan, RogerJose, SophieBucher, Heiner CScherrer, Alexandra UReiss, Petervan Sighem, ArdBoender, T SoniaPorter, KholoudGilson, RichardParaskevis, DimitriosSimeon, MetallidisVourli, GeorgiaMoreno, SantiagoJarrin, InmaculadaSabin, CarolineHernán, Miguel AMR/M004236/1/MRC_/Medical Research Council/United KingdomJournal ArticleUnited StatesJ Acquir Immune Defic Syndr. 2019 Nov 1;82(3):314-320. doi: 10.1097/QAI.0000000000002135.